This event is hosted and organized by NYC Bio in conjunction with BioPharma Club of NY&NJ:
Location: Varick St. Incubator, 137 Varick St., Floor 2
Date: Thursday Sept 27th 2012
“The Drug Discovery Process: Delivering novel therapies for unmet medical needs”
Our event will bring together scientific investigators from biotechnology, pharmaceutical companies and academic institutions in New York City metropolitan area.
Selected panelists will share their thoughts, experiences and advice on pre-clinical drug discovery of small molecules and biologics. This informal session should attract principal investigators, academic researchers and entrepreneurs interested in transforming ideas into innovative drug candidates.
Brief speaker presentations and an interactive panel discussion will be preceded and followed by ample networking time. Food and Refreshments will be provided.
Please RSVP/reply at the NYC Bio meetup site (http://www.meetup.com/biotech-40/)
Michelle Lewis, Vice President of Intellectual Property, Molecular Templates
Boris Shor, Principal Scientist, Pfizer Oncology
Robert Rollins, Principal Scientist, Pfizer Oncology
Michelle recently joined Molecular Templates, a small biotech company located in Austin, TX and Newark, NJ, as their Vice President of Intellectual Property. Before that she worked for eight years for ZymoGenetics (now Bristol Myers Squibb) in Seattle, WA where she served as a member of the Exploratory Group Committee, aiding decision-making on the company's earliest stage projects. She spent nine years working in law firms before going in-house where clients included NIH, Lonza, American Home Products, Microsoft and start-up biotechnology companies. During this time she attended Rutgers-Newark School of Law where she was on Law Review, Order of the Coif, and graduated with honors. Michelle has worked as a patent examiner at the USPTO, and has a Master's Degree in Genetics from Columbia University and a Bachelor of Science degree from Duke University.
Boris Shor is a Principal Scientist in the Oncology Research Unit of Pfizer Research and Development. In this role, Dr. Shor is leading research projects to develop novel antibody drug conjugates therapeutics for hematologic malignancies and solid tumors. Prior to the acquisition of Wyeth in 2009, he was a Senior Scientist at the department of Oncology Drug Discovery at Wyeth Pharmaceuticals, where he studied mechanism of action of existing mTOR inhibitors and contributed to the discovery of novel small molecules targeting mTOR/PI3K pathway. Before joining Wyeth in 2003, Boris performed a postdoctoral fellowship in the Inflammation Research team at Johnson & Johnson Pharmaceutical R&D. Boris received his Ph.D. in Molecular and Cell Biology from the SUNY Downstate Medical Center, New York.
Robert Rollins is a Principal Scientist in Oncology Research Unit of Pfizer's Research and Development Organization, where his work is focused on the discovery of novel epigenetic therapies for the treatment of cancer. Before joining Pfizer, Robert was a Principal Research Scientist in the Oncology Discovery Unit of Wyeth Research. Prior to joining Wyeth in 2006, he was a Research Scientist at Enzo Life Sciences, a subsidiary of Enzo Biochem. He completed a post-doctoral fellowship in Epigenetics at Columbia University in the Department of Genetics and Development. Robert holds a Ph.D. in Molecular Biology and Genetics from the Cornell University Weill Graduate School of Medical Sciences.